ReportGem ReportGem

GLOBAL RESEARCH ARCHIVE

Springer Nature AG & Co KgaA: 1H26: 3% adj. EBIT beat, FY26 guidance raised

Published: 2026-08-05Institution: Morgan StanleyCompany / ticker: SPGG.DEPages: 8Original language: 英语

Research evidence excerpt

M

Update

August 5, 2026 06:49 AM GMT

Springer Nature AG & Co KgaA | Europe

Morgan Stanley & Co. International plc+

David Nolan

Equity Analyst

1H26: 3% adj. EBIT beat, FY26

guidance raised

Ed Young

Equity Analyst

Springer Nature AG & Co KgaA (SPGG.DE, SPG GR)

Media & Entertainment | Germany

AlphaSignals Earnings Reaction

Unchanged

Modest upside

Modest revision higher

Impact to our thesis

Financial results versus consensus

Direction of next 12-month

consensus EPS

Source: Company data, Morgan Stanley Research

Key Takeaways

Stock Rating

Industry View

Price target

Shr price, close (Aug 4, 2026)

52-Week Range

Mkt cap, curr (mn)

Net debt (12/26e) (mn)*

EV, curr (mn)*

Overweight

In-Line

€26.90

€18.62

€24.65-14.70

€3,703

€1,016

€4,862

* = GAAP or approximated based on GAAP

6.2% underlying revenue growth for 1H versus consensus 5.6%. 1H underlying adj.

EBIT grew 7.7% and was 2.0%/2.8% above MSe/consensus

Research division +7.2% underlying in 1H (vs. 7.2% in Q1), Health +1.3% underlying,

Education +3.5% underlying.

FY26 guidance raised to c. 6% underlying revenue growth and at least 30bps of

underlying AOP margin expansion, from 5–6% and c. 30bps previously

At c. 0.8x PEG on MSe, we think valuation remains clearly attractive. We expect

the stock to outperform today

Summary. Springer Nature has delivered a strong 1H26, with revenue of €939.8m,

up 6.2% underlying versus MSe/consensus at 5.9%/5.6%. Adj. EBIT of €246.2m grew

7.7% underlying and was 2.0%/2.8% ahead, with the 26.2% margin representing

38bps of underlying expansion. Within the mix, research remained the main driver.

Reported revenue was broadly in line, but underlying growth of 7.2% exceeded MSe/

consensus at 7.0%/6.9%, while adj. EBIT was 2%/3% ahead as c. 13% article

publication growth (market growing at 8%), operating leverage and efficiency

measures supported a 30.6% margin. Nearly all 2026 contract renewals have also

now been completed. Education revenue was 4%/5% ahead of MSe/consensus,

while Health was broadly in line. FCF of €267.6m was c. 30% above MSe, supported

by the operating performance and lower interest payments, although with some

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer